bioequivalence of drug combination [Regulatives / Guidelines]

posted by balakotu – India, 2018-04-13 08:40 (2177 d 01:37 ago) – Posting: # 18675
Views: 1,673

(edited by Ohlbe on 2018-04-13 10:22)

Hello Norah,
As per USFDA, it is mandatory to perform separate studies for separate products.
FDA will not accept plain candesartan ANDA without BE studies.
Moreover, candesartan a BCS class II product and waiver approach (based on combination product BE study) is not possible to get the waiver for plain Candesartan.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
100 visitors (0 registered, 100 guests [including 7 identified bots]).
Forum time: 09:17 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5